SOFTGEL COMMERCIAL MANUFACTURING AGREEMENTSoftgel Commercial Manufacturing Agreement • May 23rd, 2014 • Clarus Therapeutics Inc • Pharmaceutical preparations • New Jersey
This Softgel Commercial Manufacturing Agreement (“Agreement”) is made this 23rd day of July, 2009, by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 2725 Scherer Drive, St. Petersburg, Florida 33716 (“Catalent”) and Clarus Therapeutics, Inc., a corporation, having its principal place of business at 500 Skokie Blvd., #250, Northbrook, IL 60062 (“Client”).
Certain information identified by [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. AMENDMENT NUMBER THREE TO THE SOFTGEL COMMERCIAL MANUFACTURING AGREEMENTSoftgel Commercial Manufacturing Agreement • June 25th, 2021 • Blue Water Acquisition Corp. • Biological products, (no disgnostic substances)
This Amendment Number Three (“Amendment Number Three”) is made this 5th day of June, 2017 (the “Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”) and Clarus Therapeutics, Inc., a corporation, having its principal place of business at 555 Skokie Blvd., #340, Northbrook, IL 60062 (“Clarus”).
Certain information identified by [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. AMENDMENT NUMBER TWO TO THE SOFTGEL COMMERCIAL MANUFACTURING AGREEMENTSoftgel Commercial Manufacturing Agreement • June 25th, 2021 • Blue Water Acquisition Corp. • Biological products, (no disgnostic substances)
This Amendment Number Two (“Amendment Number Two”) is made this of 12 day of November, 2012 (the “Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”) and Clarus Therapeutics, Inc., a corporation, having its principal place of business at 555 Skokie Blvd., #340, Northbrook, IL 60062 (“Clarus”).
SOFTGEL COMMERCIAL MANUFACTURING AGREEMENTSoftgel Commercial Manufacturing Agreement • November 19th, 2010 • Clarus Therapeutics Inc • New Jersey
This Softgel Commercial Manufacturing Agreement ("Agreement") is made this 23rd day of July, 2009, by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 2725 Scherer Drive, St. Petersburg, Florida 33716 ("Catalent") and Clarus Therapeutics, Inc., a corporation, having its principal place of business at 500 Skokie Blvd., #250, Northbrook, IL 60062 ("Client").
Certain information identified by [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. AMENDMENT NUMBER ONE TO THE SOFTGEL COMMERCIAL MANUFACTURING AGREEMENTSoftgel Commercial Manufacturing Agreement • June 25th, 2021 • Blue Water Acquisition Corp. • Biological products, (no disgnostic substances)
This Amendment Number One (“Amendment Number One”) is made this 23rd day of October, 2012 (the “Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”) and Clarus Therapeutics, Inc., a corporation, having its principal place of business at 555 Skokie Blvd., #340, Northbrook, IL 60062 (“Clarus”).
Certain information identified by [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. SOFTGEL COMMERCIAL MANUFACTURING AGREEMENTSoftgel Commercial Manufacturing Agreement • June 25th, 2021 • Blue Water Acquisition Corp. • Biological products, (no disgnostic substances) • New Jersey
This Softgel Commercial Manufacturing Agreement (“Agreement”) is made this 23 day of July 2009, by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 2725 Scherer Drive, St. Petersburg, Florida 33716 (“Catalent”) and Clarus Therapeutics, Inc., a corporation, having its principal place of business at 500 Skokie Blvd., #250, Northbrook, IL 60062 (“Client”).
